|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_on1242107331 |
| 003 |
OCoLC |
| 005 |
20231120010535.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
210318s2021 enk o 001 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d OPELS
|d OCLCO
|d EBLCP
|d OCLCF
|d RDF
|d OCLCO
|d OCLCQ
|d OCLCO
|d COM
|d OCL
|d OCLCQ
|d N$T
|d OCLCO
|
| 020 |
|
|
|a 9780128244845
|q (electronic bk.)
|
| 020 |
|
|
|a 0128244844
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128199855
|
| 020 |
|
|
|z 0128199857
|
| 035 |
|
|
|a (OCoLC)1242107331
|
| 050 |
|
4 |
|a RC311
|
| 082 |
0 |
4 |
|a 616.995069
|2 23
|
| 245 |
0 |
0 |
|a Mechanistic approach to medicines for tuberculosis nanotherapy /
|c edited by Mariappan Rajan.
|
| 260 |
|
|
|a London :
|b Academic Press,
|c 2021.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Includes index.
|
| 505 |
0 |
|
|a Intro -- A Mechanistic Approach to Medicines for Tuberculosis Nanotherapy -- Copyright -- Contents -- Contributors -- Chapter 1 Basics of tuberculosis disease and principles of treatment and their effects -- 1 Introduction -- 2 Host response to Mtb infection -- 3 Role of innate immune cells against Mtb infection -- 3.1 Macrophage -- 3.2 Neutrophil -- 3.3 Dendritic cell -- 3.4 Natural killer cells -- 4 Immune factors involved in Mtb recognition -- 4.1 Complement factors and complement receptors -- 4.2 Mannose receptor -- 4.3 Collectins -- 4.4 Toll-like receptors
|
| 505 |
8 |
|
|a 7 Adaptive immune response against TB infection -- 7.1 Humoral response to TB infection -- 7.2 Cell-mediated response to TB infection -- 8 Immune evasion strategy by Mycobacterium tuberculosis -- 9 Treatment for tuberculosis infection and side effects -- 10 Drug-resistant TB -- 10.1 Types of drug-resistant TB -- 11 TB diagnosis -- 11.1 Smear microscopy -- 11.2 Culture methods and drug susceptibility testing -- 11.3 Molecular diagnosis -- 11.4 GeneXpert MTB/RIF -- 11.5 Line probe assays -- 11.6 Sequencing -- 12 Diagnosis of latent TB infection -- 13 Conclusion -- References
|
| 505 |
8 |
|
|a Chapter 2 The pulmonary administration route: Advantages and challenges -- 1 Introduction -- 1.1 Transmission and pathogenesis of TB bacteria -- 1.2 Current therapeutics for treating TB and their limitations -- 2 Pulmonary drug delivery system (PDDS) -- 2.1 Lung as an attractive target for pulmonary drug delivery -- 2.2 Administration and deposition of inhaled particles on the lung -- 2.3 Clearance mechanism of the administrated particles in the pulmonary system -- 2.3.1 Mucociliary clearance -- 2.3.2 Alveolar clearance -- 3 Pulmonary drug administration -- 3.1 Drug delivery systems
|
| 505 |
8 |
|
|a 3.1.1 Liposomes -- 3.1.2 Proliposomes -- 3.1.3 Liposphere -- 3.1.4 Nanocarrier systems -- 3.1.5 Polymeric nanoparticles -- 3.1.6 Polymeric micelles -- 4 Advantages of the pulmonary administration route -- 5 Current advances in pulmonary drug delivery -- 6 Factors affecting pulmonary drug delivery -- 6.1 Physical factors affecting aerosol deposition -- 6.1.1 Inspiratory -- 6.1.2 Aerosol generation -- 6.1.3 Tidal volume -- 6.1.4 Breath -- 6.1.5 Disease states -- 6.2 Pharmaceutical factors affecting aerosol deposition -- 6.2.1 Aerosol -- 6.2.2 Size -- 6.2.3 Shape -- 6.2.4 Density
|
| 650 |
|
0 |
|a Tuberculosis
|x Treatment.
|
| 650 |
|
0 |
|a Nanomedicine.
|
| 650 |
|
0 |
|a Tuberculosis.
|
| 650 |
1 |
2 |
|a Tuberculosis
|0 (DNLM)D014376
|
| 650 |
1 |
2 |
|a Tuberculosis
|x therapy
|0 (DNLM)D014376Q000628
|
| 650 |
2 |
2 |
|a Nanomedicine
|x methods
|0 (DNLM)D050997Q000379
|
| 650 |
|
2 |
|a Nanomedicine
|0 (DNLM)D050997
|
| 650 |
|
6 |
|a Tuberculose
|0 (CaQQLa)201-0035713
|x Traitement.
|0 (CaQQLa)201-0377521
|
| 650 |
|
6 |
|a Tuberculose.
|0 (CaQQLa)201-0035713
|
| 650 |
|
6 |
|a Nanom�edecine.
|0 (CaQQLa)201-0448752
|
| 650 |
|
7 |
|a Tuberculosis
|2 fast
|0 (OCoLC)fst01158499
|
| 650 |
|
7 |
|a Nanomedicine
|2 fast
|0 (OCoLC)fst01744350
|
| 650 |
|
7 |
|a Tuberculosis
|x Treatment
|2 fast
|0 (OCoLC)fst01158551
|
| 700 |
1 |
|
|a Rajan, Mariappan.
|
| 776 |
0 |
8 |
|i Print version:
|z 9780128244845
|
| 776 |
0 |
8 |
|i Print version:
|t Mechanistic approach to medicines for tuberculosis nanotherapy.
|d London : Academic Press, 2021
|z 0128199857
|z 9780128199855
|w (OCoLC)1159167789
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128199855
|z Texto completo
|
